secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bio Green Med Solution, Inc. (BGMS)
CIK:        0001130166
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001104659-22-116489
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclacel Q3: net loss $5.1M, cash $23.7M; oral fadraciclib shows 2 partial responses in T-cell lymphoma
--------------------------------------------------------------------------------

- Cash $23.7M at Sept 30, 2022 (vs $36.6M at Dec 31, 2021); cash runway expected to fund programs to end of 2023.
- Oral fadraciclib Phase 1/2: 18 evaluable patients; 2/3 partial responses in T-cell lymphoma, 11 stable diseases across solid tumors.
- Oral CYC140 Phase 1/2: no DLTs; durable stable disease at first dose level in ovarian and KRAS G12V NSCLC patients.
- Terminating sapacitabine license with Daiichi Sankyo, effective March 23, 2023; not pursuing further development.
- Expect to determine RP2D for fadraciclib in 4Q 2022 and start Phase 2 in 1H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130166/000110465922116489/0001104659-22-116489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130166/000110465922116489/tm2230005d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-116489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer